Global Drug Updates & Innovation Trends in H1 2026

Since the beginning of 2026, the global pharmaceutical industry has accelerated across drug R&D, clinical breakthroughs, regulatory approvals and technological innovation, with multiple milestones reshaping treatment standards and expanding patient options.

1. Rising Global Impact of Chinese Innovative Drugs

In immuno-oncology, ivonescimab (PD‑1/VEGF bispecific antibody), a China-originated first-in-class asset, presented pivotal HARMONi‑6 data at the 2026 ASCO Plenary Session: as first-line therapy for advanced squamous NSCLC, it reduced the risk of death by 34% versus standard care, with a median OS of 27.9 months. This marks the first time a Chinese First-in-class drug has been featured in the ASCO Plenary Session in 61 years, signifying China’s entry into the global innovation elite.

In hematology, sovleplenib (HUTCHMED) reported positive Phase III ESLIM‑02 data in warm antibody autoimmune hemolytic anemia (wAIHA) at EHA 2026. It has received Breakthrough Therapy Designation and Priority Review from China NMPA, poised to become the first approved targeted therapy for wAIHA.

2. Intensive Approvals Worldwide for Blockbuster Drugs

In China, early June 2026 saw NMPA grant conditional approvals for anrucentinib, lobrutinib, pomitase alfa, sbelimab, covering solid tumors, hematologic malignancies and rare diseases. A traditional Chinese medicine innovation, Zaoren Ningxin Dripping Pills, was also approved, advancing TCM modernization国家药品监督管理局.

Globally, the FDA granted accelerated approval to Hepcludex (bulevirtide), the first chronic hepatitis D treatment in the U.S., ending a 40-year therapeutic gap. The world’s first PROTAC, Veppanu (vepdegestrant), was approved for ER+/HER2‑mutated advanced breast cancer, inaugurating a new era of targeted protein degradation.

3. AI & New Technologies Reshape R&D Paradigms

The FDA launched an AI Accelerated Pathway Pilot, selecting 10 companies with AI-discovered drugs for expedited Phase I review. AI is increasingly adopted in molecular design, virtual screening, patient stratification and endpoint prediction, substantially shortening timelines and reducing failure rates.

Conclusion

2026 is defined by three themes: the rise of Chinese innovation, accelerated global approvals, and tech-driven transformation. As more Phase III data mature and regulatory decisions emerge, breakthrough therapies will continue to launch in oncology, autoimmunity, rare diseases and anti-infectives, delivering greater access and better outcomes for patients worldwide.